Skip to search formSkip to main contentSkip to account menu

MDL 100240

Known as: MDL 100,240, MDL-100240, MDL-100,240 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzazepinesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension
Objective The renoprotective action of angiotensin I-converting enzyme inhibitors (ACE-Is) is well established, but the role… 
2004
2004
Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240
Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin‐converting enzyme (ACE) has gained increasing interest in… 
2003
2003
Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers
M100240 is the thioester of MDL 100,173, a dual angiotensin‐converting enzyme (ACE)/neutral endopeptidase (NEP) inhibitor… 
2003
2003
Permeation prediction of M100240 using the parallel artificial membrane permeability assay.
PURPOSE Kansy et al first introduced the Parallel artificial membrane permeation assay (PAMPA) in 1998. In this system, the… 
2002
2002
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor
Objective To investigate the effects of the dual angiotensin-converting enzyme (ACE) + neutral endopeptidase (NEP) inhibitor, MDL… 
2002
2002
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
2000
2000
Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers
AbstractBackground: MDL 100,240 (pyrido[2,1-a] [2]benzazepine-4-carboxylic acid,7-[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1… 
1998
1998
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy…
MDL 100,240, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), was administered… 
1997
1997
Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats
1 The effects of combined inhibition of neutral endopeptidase 24.11 and angiotensin‐converting enzyme, with the dual… 
1997
1997
Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen‐2)27) rats
1 Heterozygous, male, hypertensive, transgenic ((mRen‐2)27) rats (350–450 g) were instrumented for the measurement of regional or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)